OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
US Stock MarketDetailed Quotes
APDN Applied DNA Sciences
- 1.660
- -0.100-5.68%
Close Mar 31 16:00 ET
- 1.719
- +0.059+3.54%
Post 20:01 ET
1.83MMarket Cap-0.05P/E (TTM)
1.700High1.450Low1.20MVolume1.650Open1.760Pre Close1.94MTurnover125.42%Turnover RatioLossP/E (Static)1.10MShares430.00052wk High0.14P/B1.59MFloat Cap1.45052wk Low--Dividend TTM959.97KShs Float35999976.000Historical High--Div YieldTTM14.21%Amplitude1.450Historical Low1.608Avg Price1Lot Size
Applied DNA Sciences Key Stats
Quarterly+Annual
YOY
| (Q1)Dec 31, 2024 | (FY)Sep 30, 2024 | (Q4)Sep 30, 2024 | (Q3)Jun 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 34.28%1.2M | -74.33%3.43M | 4.28%813.11K | -72.66%797.52K | -78.91%929.63K | -83.07%891.16K | -26.43%13.37M | -78.09%779.74K | -32.10%2.92M | -28.30%4.41M |
| Operating revenue | 34.28%1.2M | -74.33%3.43M | 4.28%813.11K | -72.66%797.52K | -78.91%929.63K | -83.07%891.16K | -26.43%13.37M | -78.09%779.74K | -32.10%2.92M | -28.30%4.41M |
| Cost of revenue | -22.35%512.51K | -69.18%2.41M | -18.91%568.21K | -66.49%552.29K | -75.62%633.98K | -77.12%660.07K | -40.27%7.83M | -77.70%700.74K | -49.40%1.65M | -28.93%2.6M |
| Gross profit | 196.03%684.11K | -81.62%1.02M | 210.01%244.9K | -80.68%245.23K | -83.64%295.65K | -90.28%231.1K | 9.49%5.53M | -81.05%79K | 22.14%1.27M | -27.37%1.81M |
| Operating expense | -9.25%3.65M | -8.77%15.04M | -17.26%3.52M | -13.00%3.59M | -13.26%3.91M | 11.77%4.02M | -13.33%16.49M | -8.98%4.25M | 5.97%4.13M | -2.83%4.51M |
| Selling and administrative expenses | -14.63%2.63M | -10.22%11.45M | -18.92%2.68M | -18.63%2.68M | -14.83%3M | 17.48%3.08M | -15.54%12.75M | -11.85%3.31M | 8.55%3.29M | -1.40%3.52M |
| Research and development costs | 8.46%1.02M | -3.78%3.59M | -11.42%831.71K | 9.20%913.03K | -7.64%913.19K | -3.65%935.82K | -4.86%3.74M | 2.85%938.91K | -3.12%836.12K | -7.60%988.74K |
| Operating profit | 21.77%-2.96M | -28.04%-14.02M | 21.57%-3.27M | -17.05%-3.35M | -33.79%-3.62M | -210.84%-3.79M | 21.59%-10.95M | 1.92%-4.17M | -0.09%-2.86M | -25.52%-2.7M |
| Net non-operating interest income expense | 114.39%71.44K | 134.03%176.3K | 121.54%91.33K | 35.52%36.3K | 321.87%15.35K | 804.04%33.32K | 946.28%75.33K | 2,872.17%41.22K | 26.78K | -34.31%3.64K |
| Non-operating interest income | 114.39%71.44K | 134.03%176.3K | 121.54%91.33K | 35.52%36.3K | 321.87%15.35K | 804.04%33.32K | 946.28%75.33K | 2,872.17%41.22K | --26.78K | -34.31%3.64K |
| Other net income (expense) | -91.47%223.85K | 690.62%6.76M | -126.04%-133.82K | 1,930.60%5.16M | -127.41%-891.38K | 199.87%2.63M | -84.98%855.04K | -85.67%513.95K | -116.28%-281.87K | 736.09%3.25M |
| Gain on sale of security | -90.75%244K | 692.26%6.77M | -125.78%-134K | 1,953.45%5.16M | -127.56%-895.97K | 200.05%2.64M | -85.11%854.4K | -85.53%519.7K | -115.83%-278.4K | 731.08%3.25M |
| Other non- operating income (expenses) | -48.86%-20.15K | -1,482.71%-8.88K | 103.18%183 | 97.09%-101 | 593.04%4.58K | -253.04%-13.54K | 101.36%642 | -41.06%-5.75K | 86.84%-3.47K | 129.17%661 |
| Income before tax | -136.11%-2.67M | 29.28%-7.09M | 8.35%-3.31M | 159.39%1.85M | -915.31%-4.49M | 70.60%-1.13M | -21.20%-10.02M | -444.07%-3.62M | -176.87%-3.11M | 131.32%551.18K |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -136.11%-2.67M | 29.28%-7.09M | 8.35%-3.31M | 159.39%1.85M | -915.31%-4.49M | 70.60%-1.13M | -21.20%-10.02M | -444.07%-3.62M | -176.87%-3.11M | 131.32%551.18K |
| Net income continuous Operations | -136.11%-2.67M | 29.28%-7.09M | 8.35%-3.31M | 159.39%1.85M | -915.31%-4.49M | 70.60%-1.13M | -21.20%-10.02M | -444.07%-3.62M | -176.87%-3.11M | 131.32%551.18K |
| Minority interest income | -16.36%-29.3K | -26.27%-95.79K | 27.31%-17K | -109.96%-30.3K | 37.29%-23.31K | -2,781.12%-25.18K | -3,398.94%-75.86K | -1,651.84%-23.39K | -2,405.03%-14.43K | -3,242.36%-37.17K |
| Net income attributable to the parent company | -138.84%-2.64M | 29.70%-6.99M | 8.23%-3.3M | 160.64%1.88M | -859.84%-4.47M | 71.25%-1.11M | -20.31%-9.95M | -441.64%-3.59M | -175.73%-3.1M | 133.45%588.34K |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | 19,071.55%14.91M | 233.09K | 0 | 0 | 155.33K | 77.76K | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -1,383.41%-17.55M | 27.36%-7.23M | 8.23%-3.3M | 160.64%1.88M | -886.24%-4.63M | 69.22%-1.18M | -18.73%-9.95M | -441.64%-3.59M | -175.73%-3.1M | 131.48%588.34K |
| Basic earnings per share | 67.63%-28 | 88.03%-91 | 94.04%-15.9852 | 109.79%23.5 | -683.52%-265.5 | 71.17%-86.5 | 18.23%-760.5 | -2,780.00%-268 | -84.62%-240 | 119.78%45.5 |
| Diluted earnings per share | 67.63%-28 | 88.03%-91 | 94.04%-15.9852 | 109.79%23.5 | -683.52%-265.5 | 71.17%-86.5 | 18.23%-760.5 | -2,780.00%-268 | -84.62%-240 | 119.78%45.5 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025